X

Trial Profile

Phase I Study of GDC-0068 as a Single Agent and in Combination with Other Anticancer Drugs in Patients with Advanced Solid Tumors.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 May 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipatasertib (Primary) ; Abiraterone; Prednisolone
Indications Prostate cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics
Sponsors Chugai Pharmaceutical

Most Recent Events

17 Nov 2017 Status changed from active, no longer recruiting to completed.
12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
23 Feb 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com